
    
      This is a non-randomized, open-label, Phase IIA pilot study testing efficacy and safety of
      ITF2357 in a population of patients with JAK2V617F positive myeloproliferative diseases. All
      recruited patients received an initial dose of 50 mg b.i.d. of ITF2357 that was subsequently
      escalated to 50 mg t.i.d. in case of lack of significant toxicity. Treatment lasted up to a
      maximum of 24 cumulative weeks of drug administration. The study was carried out in Italy.
      Enrolled patients were subjects of both genders, with an established diagnosis of
      polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) according to
      the revised WHO criteria.
    
  